What does reboxetine do and how effective is it?

What does reboxetine do?

Serotonin and noradrenaline are neurotransmitters — chemicals that relay signals between the cells in your brain. Reboxetine increases the amount of noradrenaline (and serotonin to a small extent) in the brain, and this is how it is thought to improve the symptoms of depression.

How effective is reboxetine?

Antidepressants are all about as effective as each other (although some clinical trial results suggest that reboxetine is less effective than other antidepressants, and that it has more side effects). However, the response to antidepressants is individual, and reboxetine may be helpful for some people. Talk to your doctor if you have any concerns.

About 50% of people treated with antidepressants find their depression symptoms are halved. Although all antidepressants have shown similar efficacy when tested in groups of people in clinical trials, keep in mind that individuals can find one antidepressant works better for them than another. So if the first antidepressant you try doesn’t seem to be working for you after a few weeks, talk to your doctor about switching to another. Psychological therapy, such as cognitive behavioural therapy (CBT), could also be an option.

Find out more about

If you are starting reboxetine, see 10 things you should know about antidepressants.

You can also read more about depression and the options for treating it.

For more information

The consumer medicine information (CMI) for your brand of reboxetine is available from our website or a pharmacist. The CMI includes:

  • How to take this medicine
  • What to do if you forget to take it
  • If you take too much (overdose)
  • Things you must and must not do while taking this medicine
  • Signs of severe reactions and what to do.
References
  • Rossi S, ed. eAMH [online]. Adelaide: Australian Medicines Handbook, 2012. www.amh.net.au. (Accessed 9 February 2012).
  • Psychotropic Expert Group. Therapeutic Guidelines: Psychotropic, Version 6. In: eTG complete [CD-ROM]. Melbourne: Therapeutic Guidelines Limited; 2008.
  • Williams JW Jr, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000;132:743–56. [PubMed]
  • Pfizer Australia Pty Ltd. Edronax consumer medicine information. August 2011. (Accessed 22 March 2012).
  • Pfizer Australia Pty Ltd. Edronax product information. 1 August 2011.  (Accessed 22 March 2012).
  • National Collaborating Centre for Mental Health. Depression: the NICE guideline on the treatment and management of depression in adults (updated edition). London: National Institute for Health and Clinical Excellence, 2010. www.nice.org.uk/nicemedia/live/12329/45896/45896.pdf (accessed 9 February 2012).
  • Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746–58. [PubMed]
  • Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:c4737. [PubMed]